



**Maidstone and
Tunbridge Wells**
NHS Trust

Ref: FOI/GS/ID 7170

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

02 February 2022

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to biologic and biosimilar products within Rheumatology.

You asked:

Q1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

- a. Abatacept [Orencia]*
- b. Adalimumab [Humira]*
- c. Adalimumab Biosimilars*
- d. Apremilast [Otezla]*
- e. Baricitinib [Olumiant]*
- f. Certolizumab [Cimzia]*
- g. Etanercept [Enbrel]*
- h. Etanercept Biosimilars*
- i. Filgotinib [Jyseleca]*
- j. Golimumab [Simponi]*
- k. Guselkumab [Tremfya]*
- l. Infliximab [Remicade]*
- m. Infliximab Biosimilars*
- n. Ixekizumab [Taltz]*
- o. Risankizumab [Skyrizi]*
- p. Rituximab [MabThera]*
- q. Rituximab Biosimilars*
- r. Sarilumab [Kevzara]*
- s. Secukinumab [Cosentyx]*
- t. Tocilizumab [Ro Actemra]*
- u. Tofacitinib [Xeljanz]*
- v. Upadacitinib [Rinvoq]*

w. Ustekinumab [Stelara]

Q2. Could you please provide the numbers of patients treated for Axial Spondyloarthritis ONLY in the last 3 months with the following drugs.

a. Adalimumab [Humira]

b. Adalimumab Biosimilars

c. Certolizumab [Cimzia]

d. Etanercept [Enbrel]

e. Etanercept Biosimilars

f. Golimumab [Simponi]

g. Infliximab [Remicade]

h. Infliximab Biosimilars

i. Ixekizumab [Taltz]

j. Secukinumab [Cosentyx]

k. Upadacitinib [Rinvoq]

Trust response:

The attached and linked report can be used to answer the questions raised.

Please note: Pharmacy Reporting is now by financial month/quarter/year.



April 2020-March
2021 Rheumatology